CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-703-5069460
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/12/2020 (Estimated)
OptionableOptionable
CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings results on Monday, February, 10th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The firm had revenue of $0.04 million for the quarter. View CEL-SCI's Earnings History.
When is CEL-SCI's next earnings date?
What price target have analysts set for CVM?
1 analysts have issued 1 year price objectives for CEL-SCI's stock. Their forecasts range from $18.00 to $18.00. On average, they expect CEL-SCI's share price to reach $18.00 in the next year. This suggests a possible upside of 10.1% from the stock's current price. View Analyst Price Targets for CEL-SCI.
What is the consensus analysts' recommendation for CEL-SCI?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CEL-SCI.
Has CEL-SCI been receiving favorable news coverage?
News stories about CVM stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CEL-SCI earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for CEL-SCI.
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Kodiak Sciences (KOD), Genus (GNS), Polynovo (PNV), Vir Biotechnology (VIR), Concordia International (CXR), Mesoblast (MSB), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Paradigm Biopharmaceuticals (PAR), Bellus Health (BLU), Oxford BioMedica (OXB), Pfenex (PFNX), Starpharma (SPL), Pfenex (PFNX) and Biotest (BIO).
What other stocks do shareholders of CEL-SCI own?
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the folowing people:
- Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)
- Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)
- Dr. Eyal Talor, Chief Scientific Officer (Age 63)
- Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)
- Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77)
Who are CEL-SCI's major shareholders?
CEL-SCI's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (1.46%), Geode Capital Management LLC (1.05%), SG Americas Securities LLC (0.46%), Bank of New York Mellon Corp (0.27%), Virtus ETF Advisers LLC (0.15%) and California Public Employees Retirement System (0.13%). Company insiders that own CEL-SCI stock include Daniel H Zimmerman, Geert R Kersten, John Cipriano and Peter R Young. View Institutional Ownership Trends for CEL-SCI.
Which major investors are selling CEL-SCI stock?
Which major investors are buying CEL-SCI stock?
CVM stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Virtus ETF Advisers LLC, California Public Employees Retirement System, Renaissance Technologies LLC, Geode Capital Management LLC, Calton & Associates Inc., UBS Group AG and Principal Financial Group Inc.. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten and Peter R Young. View Insider Buying and Selling for CEL-SCI.
How do I buy shares of CEL-SCI?
Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CEL-SCI's stock price today?
One share of CVM stock can currently be purchased for approximately $16.35.
How big of a company is CEL-SCI?
What is CEL-SCI's official website?
How can I contact CEL-SCI?
CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.
MarketBeat Community Rating for CEL-SCI (NYSEAMERICAN CVM)
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
